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Tackling Overtreatment of Prostate Cancer
The Role of Comorbidity
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The management of localized prostate cancer continues to be an area of tremendous controversy. In 1 of the only clinical
trials supporting an aggressive approach, an overall survival benefit for radical prostatectomy versus watchful waiting was
limited to men aged <65 years at diagnosis and could be demonstrated only after 10 years of follow-up.1,2 In addition, a
small minority of the men were diagnosed by prostate-specific antigen (PSA) screening, making generalizability of those
results to contemporary prostate cancer cohorts questionable. Moreover, older men or men with low-risk tumors are
unlikely to die from their prostate cancer even without any aggressive intervention, such as radical prostatectomy or radia-
tion therapy.3 Therefore, although a wide variety of treatment options exists, the main challenge has been, and continues
to be, how to identify the men for whom it would be more appropriate to adopt a conservative approach.
In this issue of Cancer, Daskivich et al add to the literature in this area.4 By using data from a cohort of nearly 1500
men with prostate cancer from 2 Veterans Affairs (VA) Medical Centers in California, they examined the impact of
comorbidity on nonprostate cancer mortality with a competing risks analysis in groups stratified according to the tumor
risk criteria described by D’Amico et al.5 Daskivich et al reasoned that the outcome of nonprostate cancer mortality was of
particular interest, because it would help discern which men would be unlikely to benefit from aggressive treatment. In a
model adjusted for age, race, D’Amico et al tumor risk, and treatment received, an increasing score on the Charlson
comorbidity index predicted higher nonprostate cancer mortality. Men who had a Charlson score3, for whom the non-
prostate cancer mortality rate was 74% at 10 years, had a greater than 8-fold increase in the hazard of death from causes
other than prostate cancer compared with men who had a Charlson score of 0. In general, those men with higher Charlson
scores and/or low-risk to intermediate-risk tumors were far more likely to die from causes other than their prostate cancer.
The concept that comorbidity should be incorporated into decision-making about treatment for prostate cancer is
not new, with some prior reports dating back more than a decade.6 The advantages of this study over others include the
use of competing risk analyses to account for both nonprostate and cancer-specific mortality in estimating the hazard of
death associated with each, coupled with the heterogeneous mix of patients with respect to tumor characteristics and treat-
ment received. In addition, comorbidity was assessed through review of medical records, which may be more accurate
than the assessments in many previous studies based on administrative claims data.7 However, generalizability is likely to
be limited given the relatively small sample of patients, the fact that the cohorts were derived from only 2 centers, and the
nature of the veteran population, with its particular socioeconomic and comorbidity issues. Previous studies have
attempted to derive nomograms to predict 10-year life expectancy and have presented information on predictive accuracy,
neither of which were done in this study.8,9 Thus, the practical utility of the study findings are limited to the generality
that men with high degrees of comorbidity and low-risk to intermediate-risk tumors probably should receive conservative
management. Ultimately, we believe that the primary value of this particular investigation is that it continues the dialogue
about how best to identify the subset of patients who are unlikely to benefit from definitive treatment.
The sobering reality is that, despite calls for more conservative management of localized prostate cancer in both the
published literature and in practice guidelines, overtreatment remains rampant.10,11 An earlier publication by the same
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investigative group reported that 54% of low-risk patients
in this population with Charlson scores 3 were treated
aggressively (radical prostatectomy, radiation therapy, or
brachytherapy).12 Similar results were reported from stud-
ies that used very large, national samples of men.13,14
There also is a growing body of evidence to suggest that
treatment itself can increase noncancer mortality among
patients with pre-existing comorbid conditions. For
example, androgen-deprivation therapy has been associ-
ated with cardiovascular disease mortality among men
with prevalent cardiovascular disease.15
Which factors might account for the failure to con-
sider life expectancy in decisions about treatment for
localized prostate cancer? There may be concerns about
the ability to accurately assess life expectancy. In a Cana-
dian survey study, 191 urologists and radiation oncolo-
gists were asked to estimate the life expectancy of patients
in clinical scenarios with various patient ages and comor-
bidities.16 Life-expectancy estimates were within 3 years
of the true value (based on Markov model projections) in
only 67% of responses. In another Canadian study, Walz
et al reported only ‘‘moderate ability’’ on the part of
19 clinicians and staff to predict 10-year life expectancy in
50 patients with localized prostate cancer when provided
with age, a modified Charlson score, and specific comor-
bidities, with a mean overall predictive accuracy based on
an area under the receiver-operating curve of 0.68 (in
which 0.5 represented prediction no better than chance,
and 1.0 represented perfection).17 Clearly, any prediction
tools developed should at least improve accuracy beyond
that based on estimates made by clinicians. However, sev-
eral published nomograms based on age and comorbid-
ities have not fared substantially better, with predictive
accuracies in the range from 0.69 to 0.73.6,9,18 Even the
nomogram by Walz et al, 1 of the most accurate available,
which has a predictive accuracy of 0.84, still is far from
ideal.8 Issues relating to the assessment of comorbidity in
many of these studies may limit the accuracy of prediction
tools. Comorbidity index scores, such as the Charlson,
provide a tool to assist clinical researchers with adjustment
for the impact of comorbidity on outcomes. However, the
Charlson index is limited, in that disease severity for
comorbid conditions either is not incorporated or is only
crudely incorporated (eg, diabetes with or without end-
organ damage). Beyond issues of the accuracy of predic-
tion tools is their ease of use. Some published nomograms
probably are too complex for use in clinical practice. Even
the Charlson index, although it is implemented readily in
clinical research, may be difficult to assess in patients
within a busy practice setting. Another issue that may be
particularly challenging to overcome is statistical illiteracy,
which is exceedingly common in patients.19 Patients have
difficulty dealing with uncertainty and grasping the con-
cept of probabilities. Thus, especially when facing a cancer
diagnosis, patients may be unwilling to accept any chance
of dying from their cancer, even if the actual probability
of doing so is very small. The troubling implication is
that, unless prediction tools are virtually perfect in their
ability to discern which men will or will not die from their
prostate cancer, patients may continue to choose aggres-
sive interventions. Ongoing research into how to improve
patient decisions in prostate cancer, therefore, certainly is
welcomed.20
A final point is that many of the treatment dilem-
mas in localized prostate cancer have their origins in
inappropriate use of PSA screening. The vast majority of
prostate cancer diagnoses in the current era occur after
PSA screening, and the majority of those diagnoses are
low-risk to intermediate-risk tumors. Yet large numbers
of elderly men with comorbidities undergo PSA screen-
ing.21 If a patient is unlikely to benefit from treatment
because of age and/or comorbidity, then they should not
be screened in the first place. Efforts directed at ensuring
appropriate use of PSA screening should help make treat-
ment decisions for prostate cancer easier. Although there
are significant challenges, at the very least, discussions
with patients about the risks and benefits of PSA screen-
ing in the context of their age and comorbidities would
occur in the absence of the tremendous emotion attached
to an actual cancer diagnosis.
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